Journal Club Spotlights: Current Advancements in Non-Small Cell Lung Cancer

To participate in this activity, please:

Log in Sign Up

Overview: Keeping up with new information about non-small cell lung cancer (NSCLC) is daunting. Digesting and applying new information to clinical practice, that’s another hurdle. This accredited series is intended to help clinicians streamline the process. Each month, the editorial board of physician experts in the care of persons with NSCLC reviews the literature to identify 1 or 2 “hot-off-the-press” publications that deserve the spotlight. During a 15-minute peer-to-peer exchange, an editorial board member gains insight from the principal investigator as to why and how the trial was conducted and its implications for clinical practice.

Goal: To facilitate integration of emerging evidence into practice to improve the health outcomes of patients with non-small cell lung cancer (NSCLC) by providing researchers, clinicians, and the interprofessional, multidisciplinary team with expert review and analysis of evolving clinical research, novel therapies, and updated practice guidelines specifically for NSCLC.

Course Credit:

2.50 ACPE Contact Hours
2.50 AMA PRA Category 1 CreditsTM
2.50 ANCC Contact Hours

NOTE: Learners should claim credit only after viewing all of the course content in this 10-part series in which they wish to participate. Once credit is claimed for this course, it will not be possible to claim additional credit.

Dates:

Opens: 2026-04-03
Closes: 2027-04-03

Target Audience:

This activity was developed for medical oncologists and clinical researchers involved in the management of patients with non-small cell lung cancer (NSCLC) requiring systemic therapy. The interprofessional, multidisciplinary care team (nurses, advanced practice providers, pharmacists, pathologists) will all benefit from updated education and insights into key clinical trials and clinical practice guideline updates that are transforming the care of patients with non-small cell lung cancer.

This activity is supported by educational grants from Johnson & Johnson and Lilly.

Accreditation Information

Accreditation

In support of improving patient care, the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 2.5 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 2.5 ANCC contact hours.

NOTE: Learners should claim credit only after viewing all of the course content in this 10-part series in which they wish to participate. Once credit is claimed for this course, it will not be possible to claim additional credit.

Additional Content Planners

Chris Elder, PharmD, BCOP (Medical Writer)

Advisory Board: Boehringer Ingelheim, Janssen Scientific/Johnson & Johnson, Mirati and Pharmacosmos


Rachel Feaster, PharmD, BCOP (Peer Reviewer)
No significant relationships to disclose.

Beth Sandy, CRNP (Nurse Reviewer)

Consultant: AbbVie, Boehringer Ingelheim, Nuvation Bio, Pfizer

Speakers Bureau: Amgen, AstraZeneca, Janssen, Jazz, Lilly, Merck


All of the financial relationships listed for these individuals have been mitigated.

    Editorial Board

  • Jamie E. Chaft, MD headshot

    Jamie E. Chaft, MD

    Attending Physician
    Thoracic Oncology
    Memorial Sloan Kettering Cancer Center
    New York, New York

  • Isabel Preeshagul, DO, MBS headshot

    Isabel Preeshagul, DO, MBS

    Thoracic Medical Oncologist
    Memorial Sloan Kettering Cancer Center
    New York, New York

    • Investigators

  • Jonathan W. Goldman, MD headshot

    Jonathan W. Goldman, MD

    Health Sciences Clinical Professor
    Division of Hematology-Oncology
    Department of Medicine
    David Geffen School of Medicine at UCLA
    Los Angeles, California

  • Aaron S. Mansfield, MD headshot

    Aaron S. Mansfield, MD

    Professor of Oncology, Mayo Clinic College of Medicine and Science
    Co-Director, Mayo Clinic Center for Individualized Medicine; Precision Cancer Therapeutics Program
    Consultant, Division of Medical Oncology, Department of Oncology Mayo Clinic
    Rochester, Minnesota

  • Jonathan W. Riess, MD, MS headshot

    Jonathan W. Riess, MD, MS

    Professor
    Department of Internal Medicine
    Division of Hematology/Oncology
    UC Davis School of Medicine
    UC Davis Comprehensive Cancer Center
    Sacramento, California

Learning Objectives

  • Assess pharmacology mechanisms and biomarker utilization for novel and emerging therapies for advanced/metastatic NSCLC
  • Describe emerging evidence and clinical data related to treatment advances for patients with metastatic/advanced NSCLC to improve clinician understanding and appreciation for novel therapies
  • Incorporate novel therapies and treatment strategies into the management of patients with advanced/metastatic NSCLC consistent with evolving evidence and practice guidelines

Faculty Disclosures

Jamie E. Chaft, MD

Adjudication Committee: Lilly

Advisory Board: AstraZeneca; Boehringer Ingelheim; EMD Serono; Exact Sciences; Foundation Medicine; Natera; Nuvation Bio; Revolution Medicines

Speakers Bureau / Invited Speaker: Merck; Roche-Genentech

Research Support: AstraZeneca; BioNTech RNA Pharmaceuticals GmbH; Boehringer Ingelheim; Genentech; Merck; Taiho Oncology

Non-Financial Relationships (Advisory Roles): Boehringer Ingelheim; Lilly; Merck; Taiho Oncology


Isabel Preeshagul, DO, MBS

Advisory Board: AbbVie, AstraZeneca, Boehringer Ingelheim, Johnson & Johnson, Nuvalent, Pfizer, Regeneron, Takeda